Research programme: Helicobacter pylori vaccine - MIVAC Development
Latest Information Update: 05 Aug 2024
At a glance
- Originator Sahlgrenska Academy
- Developer MIVAC Development
- Class Vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Helicobacter infections
Most Recent Events
- 29 Jul 2024 Genentech plans a phase II BRAVE trial for Chronic lymphocytic leukemia (First-line therapy, Combination therapy) in August 2024 (PO) (NCT06524375)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Helicobacter-infections in Sweden
- 21 Jul 2011 Preclinical trials in Helicobacter infections in Sweden (unspecified route)